Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell
lung cancer (SCLC) patients without disease progression after first-line platinum containing
chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression
after first-line platinum containing chemotherapy, and orr in SCLC patients with recurrence
or progression after second-line and above treatment,Evaluation of the effectiveness of
al8326 monotherapy in small cell lung cancer.
This trial is a multicenter, single arm, open label, nonrandomized, phase Ib / IIA trial that
will evaluate the preliminary efficacy and safety of AL8326 in patients with small cell lung
cancer (SCLC).Three treatment groups were used in this trial, and the study population,
sample size, and basic design of each group were as follows:
Group A: Patients with small-cell lung cancer without disease progression (in remission [PR
or Cr] or stable disease [SD] status) after first-line platinum containing chemotherapy were
included, with a total sample size expected to be 79 patients.
Group B: Patients who relapsed or progressed after first-line platinum containing
chemotherapy regimens, with a total sample size expected to be 79 patients.
Group C: Patients with small cell lung cancer who have relapsed or progressed after at least
one line of treatment (including first-line platinum containing therapy, second-line single
agent or other) with a total sample size expected to be 79 patients.
Small Cell Lung Cancer,
small cell carcinoma,
small cell carcinoma of the lung
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.